Results 131 to 140 of about 3,831 (231)

2816. Comparative Effectiveness of Meropenem/Vaborbactam vs. Ceftazidime/Avibactam among Adults Hospitalized with an Infectious Syndrome in the US, 2019-2021 [PDF]

, 2023
Marya D. Zilberberg, Brian H. Nathanson, Mark Redell, Kate Sulham, Andrew F. Shorr   +4 more
openalex   +1 more source

Genotypic Evolution of Klebsiella pneumoniae Sequence Type 512 during Ceftazidime/Avibactam, Meropenem/Vaborbactam, and Cefiderocol Treatment, Italy

, 2023
Gabriele Arcari, Federico Cecilia, Alessandra Oliva, Riccardo Polani, Giammarco Raponi, Federica Sacco, Alice De Francesco, Francesco Pugliese, Alessandra Carattoli   +8 more
openalex   +1 more source

1114. Exploring bactericidal activity and emergence of resistance for carbapenem-resistant Enterobacterales (CRE) with and without Klebsiella pneumoniae carbapenemase (KPC) treated with optimized meropenem (MEM) and meropenem-vaborbactam (MEV) exposures [PDF]

, 2023
Kevin M Squires, Ellen G Kline, Chelsea E Jones, Ryan K. Shields   +3 more
openalex   +1 more source

Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient [PDF]

, 2018
Vasilios Athans, Elizabeth Neuner, Habiba Hassouna, Sandra S. Richter, George Keller, Mariana Castanheira, Kyle D. Brizendine, Amy J. Mathers   +7 more
openalex   +1 more source

UHPLC method development, validation and forced degradation study for simultaneous estimation of vaborbactam and meropenem in bulk drug

, 2021
B. Ramya Kuber, B. Geethika
openalex   +1 more source

Antimicrobial susceptibility of clinically important carbapenem-resistant Enterobacterales towards standard and new antibiotics

Journal of Global Antimicrobial Resistance
AIM: The aim of this work is to study carbapenem-resistant Enterobacterales (CRE) incidence, carbapenemase types and antimicrobial susceptibility of the strains to standard and new antibiotics.
Deniz Hamidov, Emma Keuleyan, Theodor Todorov, Radoslava Vazharova, Georgi Todorov, Atanas Syarov   +5 more
doaj   +1 more source

Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections [PDF]

, 2020
Sara Alosaimy, Sarah C J Jorgensen, Abdalhamid M Lagnf, Sarah Melvin, Ryan P. Mynatt, Travis J Carlson, Kevin W. Garey, David W. Allen, Veena Venugopalan, Michael P. Veve, Vasilios Athans, Stephen Saw, Christine Yost, Susan L. Davis, Michael J. Rybak   +14 more
openalex   +1 more source

Klebsiella pneumoniae mutants resistant to ceftazidime/avibactam plus aztreonam, imipenem/relebactam, meropenem/vaborbactam and cefepime/taniborbactam [PDF]

, 2021
Naphat Satapoomin, Punyawee Dulyayangkul, Matthew B. Avison   +2 more
openalex   +1 more source

Meropenem–Vaborbactam for the Treatment of Post-Neurosurgical Meningitis Caused by KPC Producer Klebsiella Pneumoniae: A Case Report and Review of the Literature

Antibiotics
Meningitis and ventriculitis, due to carbapenem-resistant Enterobacterales, are frequently associated with significant morbidity and mortality. In the case of multi-drug-resistant pathogens, it is necessary to consider the limited susceptibility profile ...
Leonardo Francesco Rezzonico, Francesco Peracchi, Marta Vecchi, Gabriele Bassi, Marco Merli, Nicholas Brian Bana, Giovanna Travi, Fulvio Crippa, Massimo Puoti   +8 more
doaj   +1 more source

1378. Evaluation of the In vitro Activity of Meropenem-Vaborbactam Against Carbapenem-Resistant Enterobacteriaceae, Including Isolates Resistant to Ceftazidime–Avibactam [PDF]

, 2018
William R. Wilson, Ellen G Kline, Chelsea E Jones, Kristin M. Morder, Cornelius J. Clancy, M. Hong Nguyen, Ryan K. Shields   +6 more
openalex   +1 more source